Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cholesgen Collaborates with AstraZeneca to Develop Hypercholesterolemia Candidates

publication date: Jun 16, 2023

Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca (NYSE: AZN) to develop new candidates for hypercholesterolemia and related metabolic diseases. The joint research effort will focus on selected targets from Cholesgen's early-stage portfolios. Cholesgen will be entitled to receive an initial payment, as well as a license package for each drug candidate that AstraZeneca chooses to advance into clinical development. One week ago, the AstraZeneca CICC Medical Industry Fund, a $1 billion effort to support China-based drug startups, participated in Cholesgen’s $14 million initial round. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital